Role of Src family kinases in acquired resistance to EGFR therapies in cancer.
Boerner
Julie L
JL
Karmanos Cancer Institute and Department of Pharmacology, Wayne State University, Detroit, MI 48201 USA. boernerj@karmanos.org
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068818:Cetuximab; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D019061:src-Family Kinases / Q000502:physiology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D047428:Protein Kinase Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors; D019061:src-Family Kinases; D000068818:Cetuximab